Formycon AG (FYB) AI Stock Analysis

0 Followers

Formycon AG

(BX Swiss:FYB)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Low Leverage and CapitalizationLow leverage and substantial equity give Formycon room to fund development and absorb volatility without immediate balance-sheet strain. This financial flexibility can support biosimilar pipeline investment while reducing exposure to debt-related constraints over the next several quarters.

Negative Factors

Recent Revenue ContractionRevenue fell about 10% in 2024 and 14% in 2025, indicating a recent loss of top-line momentum. Continued contraction would reduce the scale available to absorb research and development costs, weaken operating leverage, and make a return to consistent profitability more difficult.

Formycon AG Business Overview & Revenue Model

Company Description

Headquartered in Planegg, Germany, Formycon AG, founded in 1999 and formerly known as Nanohale AG until 2012, specializes in the development and commercialization of biosimilar medications. Its robust product pipeline includes FYB201, a biosimilar eq...

Formycon AG Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

CH:FYB against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
DE:BNN	44Neutral	EUR 57.46M	-4.04	590.52%	―	―	―
DE:HPHA	41Neutral	EUR 101.52M	-3.31	200.64%	―	206.78%	-13.94%

* Healthcare Sector Average

Performance Comparison

CH:FYB and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:BNN	B.R.A.I.N. Biotechnology Research and Information Network	2.67	0.21	8.54%
DE:CNW	co.don AG	0.01	-0.00	-20.00%
DE:MDG1	Medigene AG	0.01	-0.02	-66.67%
DE:HPHA	Heidelberg Pharma AG	2.12	-0.90	-29.80%
DE:MF6	MagForce AG	―	―	―

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Formycon AG AI Stock Analysis